Stock Events

Solid Biosciences 

$8.24
18
+$0.13+1.6% Monday 20:00

Statistics

Day High
8.45
Day Low
8
52W High
15.05
52W Low
1.81
Volume
170,989
Avg. Volume
486,237
Mkt Cap
344.66M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

7
NOV
Earnings
 

Earnings

7NovExpected
Q4 2022
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
-1.65
-1.3
-0.96
-0.61
Expected EPS
-0.668047
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SLDB. It's not an investment recommendation.
Alphabet
73021
GOOGL
Apple
63823
AAPL
Microsoft
59479
MSFT
Amazon
54911
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap12.95B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases, including Duchenne muscular dystrophy (DMD), directly competing with Solid Biosciences' gene therapy approaches for DMD.
PTC Therapeutics
PTCT
Mkt Cap2.72B
PTC Therapeutics is involved in the development of genetically targeted therapies for the treatment of rare diseases, including DMD, positioning it as a competitor in the same therapeutic area as Solid Biosciences.
Biomarin Pharmaceutical
BMRN
Mkt Cap17.36B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, including therapies for DMD, making it a direct competitor in the rare disease space.
Pfizer
PFE
Mkt Cap164.39B
Pfizer is engaged in the discovery, development, manufacture, and sale of healthcare products, including gene therapies for rare diseases. Its broad focus on gene therapy research can potentially compete with Solid Biosciences' DMD treatments.
Sangamo Therapeutics
SGMO
Mkt Cap176.57M
Sangamo Therapeutics focuses on genomic medicine, including gene therapy, gene editing, and gene regulation, to develop treatments for DMD among other diseases, positioning it as a competitor in the gene therapy space.
Dyadic International DE
DYAI
Mkt Cap39.5M
Dyadic International leverages its proprietary C1 gene expression platform to develop and produce biologic vaccines and drugs at flexible scales, including potential treatments for rare diseases, which may compete with Solid Biosciences' therapeutic approaches.
Ultragenyx Pharmaceutical
RARE
Mkt Cap5.23B
Ultragenyx Pharmaceutical focuses on the development of novel products for serious rare and ultra-rare genetic diseases, including muscle-related disorders, which could compete with Solid Biosciences' pipeline.
Abeona Therapeutics
ABEO
Mkt Cap246.89M
Abeona Therapeutics is focused on developing gene and cell therapies for life-threatening rare genetic diseases, including DMD, making it a direct competitor in the gene therapy market.
Bluebird bio
BLUE
Mkt Cap108.22M
bluebird bio focuses on developing gene therapies for severe genetic diseases and cancer, with a pipeline that could potentially include treatments for DMD, positioning it as a competitor in the gene therapy space.
Novartis
NVS
Mkt Cap244.75B
Novartis is a global healthcare company that, through its acquisition of AveXis, has entered the gene therapy market for spinal muscular atrophy and is exploring treatments for other genetic disorders, potentially competing with Solid Biosciences in the broader gene therapy market.

Analyst Ratings

19.14$Average Price Target
The highest estimate is $40.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Health Technology
Biotechnology
Manufacturing
Biological Product (except Diagnostic) Manufacturing
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Employees
88
Country
US
ISIN
US83422E1055

Listings

XNAS
US
SLDB